Oxford BioDynamics, a precision clinical diagnostics company, is set to present its EpiSwitch® products for companion diagnostics in cancer immunotherapy at the 14th World Summit for Clinical Biomarkers and Companion Diagnostics in Boston, MA. The company will discuss the diagnostic, predictive, and prognostic power of the EpiSwitch® platform, including the EpiSwitch CiRT, a highly accurate Immune-Oncology response test, and the EpiSwitch HiRT, a prognostic test for IO-triggered Hyperprogressive Disease. Additionally, OBD will introduce the EpiSwitch Data Knowledgebase, a database of over 1 billion data points and proprietary AI algorithms for in silico modeling of biomarkers and assays. The company has also applied for a New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) license for its EpiSwitch® CiRT. OBD's efforts aim to enhance the benefits of immunotherapy and predict side effects, addressing low response rates and life-threatening side effects.